鼻内艾司氯胺酮辅助口服抗抑郁药治疗难治性抑郁的疗效与安全性
这项2期双盲、双随机、延迟开始、安慰剂对照试验纳入67例难治性抑郁成人患者,评估鼻内艾司氯胺酮辅助口服抗抑郁药的疗效与安全性。结果显示三个剂量组第8天MADRS总分改善均优于安慰剂,呈显著剂量反应关系,开放标签阶段降低给药频率后疗效似可维持。
要点
- 鼻内艾司氯胺酮28mg、56mg、84mg组MADRS总分改善均优于安慰剂。
- 疗效呈显著 ascending 剂量反应关系(P < .001)。
- 开放标签阶段降低给药频率后抑郁症状改善似可维持。
核心结论
- 鼻内艾司氯胺酮辅助口服抗抑郁药治疗难治性抑郁起效快且呈剂量相关,降低给药频率后疗效似可维持超过2个月。
研究设计与样本
- 2期双盲、双随机、延迟开始、安慰剂对照研究,2014年1月28日至2015年9月25日在多个门诊转诊中心开展。
- 意向性治疗分析;双盲期第1期按3:1:1:1随机至安慰剂(n=33)、艾司氯胺酮28mg(n=11)、56mg(n=11)、84mg(n=12),每周两次。
主要发现
- 两个双盲期合并分析,MADRS总分较基线变化的最小二乘均值(SE)与安慰剂差异:28mg为-4.2(2.09),P=.02;56mg为-6.3(2.07),P=.001;84mg为-9.0(2.13),P<.001。
- 剂量反应关系显著(P<.001)。
- 开放标签阶段降低给药频率后抑郁症状改善似可维持(-7.2 [1.84])。
- 双盲期艾司氯胺酮组56例中3例(5%)因不良事件停药,安慰剂组无;开放标签期57例中1例(2%)因不良事件停药。
关键数值与推荐
- 主要疗效终点为每个双盲期第8天MADRS总分较基线变化。
- 双盲期第2期,28例安慰剂治疗且症状中重度的参与者按1:1:1:1重新随机至4个治疗组之一,症状轻度者继续安慰剂。
- 开放标签阶段给药频率从每周两次降至每周一次,再降至每两周一次。
临床怎么用
- 对于对2种以上抗抑郁药应答不足的难治性抑郁成人,鼻内艾司氯胺酮辅助现有口服抗抑郁药可考虑作为快速起效的增效策略。
- 剂量与安慰剂差异呈剂量依赖性,临床需权衡较高剂量下的疗效与不良事件停药风险。
- 降低给药频率后疗效似可维持,但需在监测下个体化调整。
局限性
- 样本量较小,随机67例,完成两个双盲期60例。
- 为2期研究,结果支持需在更大规模试验中进一步验证。
- 开放标签阶段无安慰剂对照,疗效维持证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. OBJECTIVE: To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). DESIGN, SETTING, AND PARTICIPANTS: This phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study was conducted in multiple outpatient referral centers from January 28, 2014, to September 25, 2015. The study consisted of 4 phases: (1) screening, (2) double-blind treatment (days 1-15), composed of two 1-week periods, (3) optional open-label treatment (days 15-74), and (4) posttreatment follow-up (8 weeks). One hundred twenty-six adults with a DSM-IV-TR diagnosis of MDD and history of inadequate response to 2 or more antidepressants (ie, TRD) were screened, 67 were randomized, and 60 completed both double-blind periods. Intent-to-treat analysis was used in evaluation of the findings. INTERVENTIONS: In period 1, participants were randomized (3:1:1:1) to placebo (n = 33), esketamine 28 mg (n = 11), 56 mg (n = 11), or 84 mg (n = 12) twice weekly. In period 2, 28 placebo-treated participants with moderate-to-severe symptoms were rerandomized (1:1:1:1) to 1 of the 4 treatment arms; those with mild symptoms continued receiving placebo. Participants continued their existing antidepressant treatment during the study. During the open-label phase, dosing frequency was reduced from twice weekly to weekly, and then to every 2 weeks. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was change from baseline to day 8 (each period) in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. RESULTS: Sixty-seven participants (38 women, mean [SD] age, 44.7 [10.0] years) were included in the efficacy and safety analyses. Change (least squares mean [SE] difference vs placebo) in MADRS total score (both periods combined) in all 3 esketamine groups was superior to placebo (esketamine 28 mg: -4.2 [2.09], P = .02; 56 mg: -6.3 [2.07], P = .001; 84 mg: -9.0 [2.13], P < .001), with a significant ascending dose-response relationship (P < .001). Improvement in depressive symptoms appeared to be sustained (-7.2 [1.84]) despite reduced dosing frequency in the open-label phase. Three of 56 (5%) esketamine-treated participants during the double-blind phase vs none receiving placebo and 1 of 57 participants (2%) during the open-label phase had adverse events that led to study discontinuation (1 event each of syncope, headache, dissociative syndrome, and ectopic pregnancy). CONCLUSIONS AND RELEVANCE: In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related. Response appeared to persist for more than 2 months with a lower dosing frequency. Results support further investigation in larger trials. TRIAL REGISTRATION: clinicaltrials.gov identifier: NCT01998958.
引用
- Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29282469. doi:10.1001/jamapsychiatry.2017.3739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。